Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
742.12
+3.40 (0.46%)
At close: Oct 7, 2026, 4:00 PM EDT
760.00
+17.88 (2.41%)
After-hours: Oct 7, 2026, 7:56 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $856.23. The average 1-year stock price forecast is 15.38% higher than the current stock price, while the lowest is $730 (-1.63%) and the highest is $1,030 (+38.79%).
Price Target: $856.23 (+15.38%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 16 | 14 | 14 | 13 | 14 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 8 | 8 | 10 | 9 | 9 | 8 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 28 | 28 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains $772 → $780 | Buy | Maintains | $772 → $780 | +5.10% | Oct 7, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $779 | Hold | Reiterates | $779 | +4.97% | Oct 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $900 → $950 | Buy | Reiterates | $900 → $950 | +28.01% | Oct 6, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Maintains $761 | Hold | Maintains | $761 | +2.54% | Oct 2, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $972 | Buy | Maintains | $972 | +30.98% | Oct 2, 2026 |
Financial Forecast
Revenue This Year
17.17B
from 14.34B
Increased by 19.72%
Revenue Next Year
18.52B
from 17.17B
Increased by 7.86%
EPS This Year
55.95
from 44.31
Increased by 26.28%
EPS Next Year
61.59
from 55.95
Increased by 10.07%
EPS and Forward PE are based on non-GAAP adjusted numbers.